Last10K.com

Novocure Ltd (NVCR) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Novocure Ltd

CIK: 1645113 Ticker: NVCR

Exhibit 99.1

Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update

 

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018

 

Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma

 

St. Helier, Jersey – Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2018. The company highlighted continued revenue growth supported by commercial momentum in newly diagnosed GBM and continued clinical development progress.

 

Third quarter 2018 highlights include:

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2018

 

 

2017

 

% Change

 

 

2018

 

 

2017

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-financial

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Active patients at period end(1)

 

2,252

 

 

1,683

 

34%

 

 

2,252

 

 

1,683

 

34%

Prescriptions received in period(2)

 

1,243

 

 

1,076

 

16%

 

 

3,745

 

 

3,029

 

24%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial, in millions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenues

$

64.8

 

$

50.1

 

29%

 

$

178.4

 

$

123.4

 

45%

Gross profit

$

45.8

 

$

35.0

 

31%

 

$

121.4

 

$

83.4

 

46%

Net loss

$

(11.7

)

$

(11.5

)

-2%

 

$

(47.9

)

$

(50.7

)

6%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at the end of period

$

123.0

 

$

82.1

 

 

 

 

 

 

 

 

 

 

Short-term investments at the end

of period

$

104.7

 

$

104.5

 

 

 

 

 

 

 

 

 

 

(1)

An “active patient” is a patient who is on Optune under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.

(2)

A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total.

 

“We delivered record quarterly revenue of $64.8 million in the third quarter, representing 5% quarter-over-quarter growth, driven by both active patient growth and ongoing improvements in our gross-to-net spread,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Prescriptions for patients with newly diagnosed GBM continued to grow, reflecting increased demand from radiation oncologists and neurosurgeons in our global active markets. We also finalized a strategic collaboration with Zai Lab which

 


The following information was filed by Novocure Ltd (NVCR) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Novocure Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novocure Ltd.

Continue

Assess how Novocure Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Novocure Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Geography
Cash Flow
Other
Inside Novocure Ltd's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Shareholders' Equity
Consolidated Statements Of Changes In Shareholders' Equity (Parenthetical)
Consolidated Statements Of Comprehensive Income (Loss)
Consolidated Statements Of Operations
Commitments And Contingent Liabilities
Commitments And Contingent Liabilities - Additional Information (Details)
Equity Incentive Plans
Equity Incentive Plans (Tables)
Equity Incentive Plans - Additional Information (Details)
Equity Incentive Plans - Schedule Of Fair Value Assumptions Used For All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)
Equity Incentive Plans - Schedule Of Non-Cash Share-Based Compensation Expenses Related To Company's Equity-Based Awards (Details)
Equity Incentive Plans - Schedule Of Rsu's (Details)
Equity Incentive Plans - Schedule Of Stock Option Plan (Details)
Inventories
Inventories (Tables)
Inventories - Schedule Of Inventories (Details)
Long Term Loan
Long Term Loan - Additional Information (Details)
Organization And Basis Of Presentation
Organization And Basis Of Presentation (Policies)
Organization And Basis Of Presentation - Additional Information (Detail)
Share Capital
Share Capital - Additional Information (Details)
Short-Term Investments
Short-Term Investments - Additional Information (Details)
Supplemental Information
Supplemental Information (Tables)
Supplemental Information - Schedule Of Long-Lived Assets By Location (Details)
Supplemental Information - Schedule Of Revenues By Geographic Region (Details)
Supplemental Information - Schedule Of Revenues By Geographic Region (Parenthetical) (Details)
Zai Lab License Agreement
Zai Lab License Agreement - Additional Information (Details)
Ticker: NVCR
CIK: 1645113
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-024994
Submitted to the SEC: Thu Oct 25 2018 6:19:22 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Sunday, September 30, 2018
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/nvcr/0001564590-18-024994.htm